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Abstract
Objective To examine the risk of treatment emergent, cardiovascular
serious adverse events associated with varenicline use for tobacco
cessation.
Design Meta-analysis comparing study effects using four summary
estimates.
Data sources Medline, Cochrane Library, online clinical trials registries,
and reference lists of identified articles.
Review methods We included randomised controlled trials of current
tobacco users of adult age comparing use of varenicline with an inactive
control and reporting adverse events. We defined treatment emergent,
cardiovascular serious adverse events as occurring during drug treatment
or within 30 days of discontinuation, and included any ischaemic or
arrhythmic adverse cardiovascular event (myocardial infarction, unstable
angina, coronary revascularisation, coronary artery disease, arrhythmias,
transient ischaemic attacks, stroke, sudden death or cardiovascular
related death, or congestive heart failure).
Results We identified 22 trials; all were double blinded and placebo
controlled; two included participants with active cardiovascular disease
and 11 enrolled participants with a history of cardiovascular disease.
Rates of treatment emergent, cardiovascular serious adverse events
were 0.63% (34/5431) in the varenicline groups and 0.47% (18/3801)
in the placebo groups. The summary estimate for the risk difference,
0.27% (95% confidence interval −0.10 to 0.63; P=0.15), based on all 22
trials, was neither clinically nor statistically significant. For comparison,
the relative risk (1.40, 0.82 to 2.39; P=0.22), Mantel-Haenszel odds ratio
(1.41, 0.82 to 2.42; P=0.22), and Peto odds ratio (1.58, 0.90 to 2.76;
P=0.11), all based on 14 trials with at least one event, also indicated a
non-significant difference between varenicline and placebo groups.
Conclusions This meta-analysis—which included all trials published to
date, focused on events occurring during drug exposure, and analysed
findings using four summary estimates—found no significant increase
in cardiovascular serious adverse events associated with varenicline
use. For rare outcomes, summary estimates based on absolute effects
are recommended and estimates based on the Peto odds ratio should
be avoided.
Introduction
Tobacco use accounts for 440 000 deaths in the United States
every year, killing nearly one in two long term smokers, with
the leading cause of death being cardiovascular disease.
1 2
Quitting smoking has immediate cardiovascular benefits,
3
reducing the risk of recurrence of coronary events to that of a
non-smoker within three years and reducing mortality after a
heart attack by up to 50% over three to five years.
4-6
USclinicalpracticeguidelinesfortreatingtobaccodependence
recommend the use of cessation pharmacotherapy for all
smokers interested in quitting, unless contraindicated.
7 The US
Food and Drug Administration has approved three first line
classes of cessation pharmacotherapy: nicotine replacement
therapy;bupropion(Zyban,Wellbutrin),anantidepressant;and
the most recently approved option, varenicline (Chantix,
Champix), a partial agonist to nicotine receptors. Varenicline
binds with high affinity and selectivity to α4β2 nicotinic
acetylcholinereceptorsinneurones.Thepartialagonistactivity
induces modest receptor stimulation that attenuates the
symptoms of nicotine withdrawal. In addition, by blocking the
ability of nicotine to activate α4β2 nicotinic acetylcholine
receptors, varenicline inhibits the surges of dopamine release
that are believed to be responsible for the reinforcement and
reward associated with tobacco use.
8 Meta-analyses and
comparative trials have demonstrated the effectiveness of
varenicline for quitting smoking and sustaining abstinence
relative both to placebo and to bupropion.
9
Forsmokerswithcardiovasculardisease,cessationofferscritical
health benefits and yet has been a challenge to achieve,
particularly in the long term.
10 A recent placebo controlled trial
ofvareniclinein714smokerswithstablecardiovasculardisease
reported sustained abstinence of 47% at the end of treatment
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Research
RESEARCHand 19% at one year follow-up in the varenicline group,
compared with 14% and 7% in the placebo group, respectively;
the group difference was significant at both time points.
11
Incidence of cardiovascular serious adverse events in the
varenicline group during the 52 week trial was low (7.0%) and
the 95% confidence interval ruled out an excess greater than
5% (1.4%, −2.3% to 5.0%). Nonetheless, the FDA has called
for systematic review of all randomised clinical trials of
varenicline for tobacco cessation to determine its association
with cardiovascular risk.
12
Singh and colleagues conducted a meta-analysis of the safety
of varenicline and concluded that the drug increased the risk of
cardiovascular serious adverse events by 72%.
13 However,
doubts about the researchers’ conclusions have been raised,
14-19
owing to several methodological issues, namely, the inclusion
of adverse events well beyond the treatment period; exclusion
of trials with no events, thereby biasing findings against the
null;anduseofthePetooddsratio,whichhasshownbiasunder
conditions of imbalanced design and rare events, which were
present in most of the reviewed trials. Inclusion of the adverse
events beyond the treatment period is of concern, because of
the elevated risk for cardiovascular disease among study
participants associated with their chronic use of tobacco and
because of differential drop out by condition. In all but one
20 of
the 14 studies reviewed by Singh and colleagues, retention was
lowerintheplacebogroupthaninthevareniclinegroup,thereby
reducing the likelihood of detecting adverse events in the
placebo arm.
We conducted a systematic review and meta-analysis of
treatment emergent, cardiovascular serious adverse events in
all published, randomised controlled trials of varenicline for
tobacco cessation. We defined these events as occurring during
drug treatment or within 30 days of discontinuation. We chose
a 30 day window because it was biologically relevant for
detecting a drug toxicity effect, while still being conservative;
the half life of varenicline is 24 hours, and any direct
pharmacologicaleffectshouldbegonewithinsevendays.Other
reports of serious adverse events to the FDA for drugs with a
similar half life have used a discontinuation period of seven
days.
21
In consideration of the low event rate and imbalanced study
designs, we summarised the study effects with the risk
difference, an estimate of absolute effect. Summaries based on
the risk difference are easily interpretable and ideal for
conveying the clinical effect of a treatment. The risk difference
provides an unbiased estimate of treatment effect, has been
shown to be particularly appropriate in examining rare event
data, and can accommodate trials with no events.
22 23 For
comparison, we also summarised the study effects with the
relative risk, Mantel-Haenszel odds ratio, and Peto odds ratio.
Methods
Literature search
Our systematic review entailed computer based searches of
Medline, the Cochrane Library, and online clinical trials
registries(ClinicalTrials.govandtheindustrysponsoredClinical
Study Results registry) to identify randomised controlled trials
evaluatingvareniclinefortobaccocessation.Thesearchcovered
January 2005 (the year when articles on varenicline were first
published) to September 2011, and included articles available
online ahead of print publication. The search strings were
“vareniclineandrandomised”inMedlineand“SR-tobaccoand
varenicline” in the Cochrane Central Register of Controlled
Trials.Wemanuallysearchedbibliographiesofrelevantresearch
and review articles.
Studiesincludedinthemeta-analysismetthefollowingcriteria:
randomised controlled design, study sample of current tobacco
users of adult age, comparing use of varenicline with that of an
inactivecontrol,andreportingadverseevents.Exclusioncriteria
included use of a quasi-experimental or crossover design,
laboratory studies with no follow-up, studies with adolescents,
studiesofnon-smokers,studiesinwhichallparticipantsreceived
varenicline,andcomparisonsofvareniclinewithanotheractive
drug (for example, nicotine replacement). Study inclusion
criteria, data extraction, and methods of the analysis were
specified in advance and documented in a protocol.
Data extraction
Two reviewers independently conducted article data extraction
and quality assessment for each study meeting the inclusion
criteria. Data extraction included descriptive characteristics of
thestudysamples;vareniclinedose;durationofdrugtreatment;
study duration; sample attrition; and the number of participants
withtreatmentemergent,cardiovascularseriousadverseevents
in the inactive and active drug conditions. For comparability,
we used the same primary outcome as Singh and colleagues,
definingcardiovascularseriousadverseeventsasanyischaemic
or arrhythmic adverse cardiovascular event (myocardial
infarction,unstableangina,coronaryrevascularisation,coronary
artery disease, arrhythmias, transient ischaemic attacks, stroke,
suddendeathorcardiovascularrelateddeath,orcongestiveheart
failure).
13
We obtained details on timing of the cardiovascular serious
adverse events from the study publications; the online clinical
trials registries; the Chantix product label; and for three trials,
for which the information was not publicly available, we
contactedthemedicaladviserforvareniclineatPfizer
11 24orthe
study lead author directly.
25 For one additional study, we
contacted the lead author to confirm that no serious adverse
events had occurred in the trial because only adverse events
were reported.
26 Discrepant findings between reviewers were
settled by discussion, further review of the article, and (if
necessary) consultation with a third reviewer.
Weassessedstudyqualityusingathreeitemmethoddeveloped
by Jadad and colleagues
27 that evaluated adequacy of
randomisation,concealmentofrandomisation,andcompleteness
of follow-up. We assessed two additional items, relevant to the
area of interest: adequate reporting and adjudication of the
cardiovascularseriousadverseevents.Noqualityscoringsystem
has proven to correlate consistently with treatment outcomes,
and it is recognised that general quality scales often need to be
supplemented with more problem specific items for each
particular meta-analysis.
28
Statistical analysis
We described trial characteristics in terms of publication date;
sample size and allocation; and participants’ exposures to
tobacco,cardiovasculardisease,andstudytreatments.Foreach
trial included in the meta-analysis, we cross classified study
participants by treatment group and by any occurrence of a
treatment emergent, cardiovascular serious adverse event. For
trialsthatexaminedmultipledosesofvarenicline,wecombined
the active treatment groups.
Using Comprehensive Meta-Analysis (version 2 professional
edition; Biostat) and fixed effects estimation, we summarised
evidence of an increased risk of cardiovascular serious adverse
events associated with varenicline use via four summary
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RESEARCHstatistics: the Mantel-Haenszel versions of the risk difference,
relative risk, and odds ratio; and the Peto odds ratio.
29 30 For
each statistic, we reported the mean effect, 95% confidence
interval, P value testing the null hypothesis of no effect, and I
2
statistic estimating heterogeneity across trials.
31 We confirmed
all results using the “metan” and “funnel” routines added to
Stata version 11. The three relative statistics excluded trials in
whicheventcountswerezeroinbotharms.
32Fortrialsinwhich
oneeventcountwasequaltozero,bothsoftwarepackages(Stata
and Comprehensive Meta-Analysis) added 0.5 to each of the
four cell counts before estimating the relative risk or
Mantel-Haenszel odds ratio.
We planned to do random effects meta-analyses and subgroup
analyses if levels of heterogeneity exceeded 50%. We plotted
the cumulative evidence by date of trial publication
33 and
examined asymmetry in a funnel plot as an indicator of
publication bias. Finally, we compared the four summary
statistics at the trial level grouping the studies by presence (v
absence) of events and equal (v unequal) numbers of events,
ordering the groups by increasing evidence of a varenicline
effect.Weexpectedthiscomparisonwouldprovideinsightinto
the most suitable summary statistic in the present setting.
Results
Study characteristics
The Medline search yielded 133 citations; of these, 21 met the
inclusion criteria, which were all published in 2006 or later (fig
1⇓). We identified one additional unpublished study from the
onlineclinicaltrialsregistries.SearchingintheCochraneCentral
Register of Controlled Trials yielded 83 results which, along
with manual searches of the bibliographies of relevant research
and review articles, did not yield any additional studies.
In total, we identified 22 randomised controlled trials of
vareniclineusefortobaccocessation;allweredoubleblindand
placebo controlled, and collectively included 9232 participants
(5431 randomised to varenicline, 3801 to placebo; table 1⇓).
Themedianoverallsamplesizewas404(range31-1210).Seven
trialshadnotableimbalancesinsamplesizebycondition—four
allocatedparticipantstovareniclineandplacebogroupsina2:1
ratio, and three studied multiple varenicline doses or regimens.
In 21 trials, the varenicline dose was 1 mg twice daily; three of
these trials also studied lower doses of varenicline (table 1).
The median duration of study treatment was 12 weeks, the
median duration of follow-up for treatment emergent,
cardiovascular serious adverse events was 16 weeks, and the
mediandurationofthestudyperiodafterrandomisationwas25
weeks.
The samples tended to have a majority of male and white
participants.Twotrialsstudiedsmokelesstobaccousers
24 34and
20 studied cigarette smokers. Among the trials of cigarette
smokers, participants averaged 21.5 cigarettes (standard
deviation 1.9) per day at study screening and 25.1 years (6.3)
of tobacco use. Thirteen trials included patients with current or
past cardiovascular disease. Of these trials, one was conducted
among smokers admitted to hospital, of whom 57% had an
admitting diagnosis that was cardiovascular
25; another was
conductedspecificallyamongpeoplewithstablecardiovascular
disease
11;and11trialsincludedpeoplewithapastcardiovascular
event (table 1). Nine trials excluded people with any history of
cardiovascular disease or the timing for exclusion was not
specified. Study quality was strong overall, with all 22 trials
beingofdoubleblinddesignandprovidingadequatedescriptions
of randomisation, loss to follow-up, and cardiovascular serious
adverse events. However, only one trial adjudicated the serious
adverse events.
11
Risk of treatment emergent, cardiovascular
serious adverse events
Across the 22 studies, the crude rates of treatment emergent,
cardiovascular serious adverse events were 0.63% (34/5431)
for the varenicline group and 0.47% (18/3801) for the placebo
group. No events occurred in eight trials, including three trials
with more than 100 participants per arm. The summary risk
difference was 0.27% (−0.10% to 0.63%, P=0.15, I
2=0%; fig
2⇓), with no indication of publication bias in the funnel plot.
Forcomparison,basedon14studieswithatleastoneevent,the
relative risk was 1.40 (0.82 to 2.39, P=0.22, I
2=0%; table 2⇓),
the Mantel-Haenszel odds ratio was 1.41 (0.82 to 2.42, P=0.22,
I
2=0%), and the Peto odds ratio was 1.58 (0.90 to 2.76, P=0.11,
I
2=0%).
Neither the individual trials nor the summary estimates showed
asignificanttreatmenteffect;consequently,wedidnotcalculate
the number needed to harm.
35 We found no evidence of
heterogeneity according to the I
2 statistic or the cumulative
estimatedeffectofvareniclineoncardiovascularseriousadverse
events (fig 3⇓).
We conducted four sensitivity analyses excluding trials of
participants with active cardiovascular disease
11 25 (risk
difference 0.29% (95% confidence interval −0.04 to 0.62),
I
2=0%); trials of smokeless tobacco users
24 34 (0.31% (−0.07 to
0.69), I
2=0%); one trial in which all participants were initially
exposed to varenicline and then randomised to placebo or to a
12 week maintenance phase of varenicline
36 (0.26% (−0.16 to
0.67, I
2=0%)); and one unpublished trial
40 (0.27% (−0.10 to
0.64, I
2=0%)). All four sensitivity analyses differed minimally
from the full analysis.
After grouping the trials by presence (v absence) of events and
equal (v unequal) numbers of events, we obtained five groups
(table 2, fig 2). Group 1 included the one trial with more
cardiovascular serious adverse events in the placebo arm than
in the varenicline group. Group 2 had no events in either arm.
Group 3 had an equal number of events per arm. Group 4 had
one or more events in the varenicline arm but none on the
placeboarm.Finally,group5hadeventsoccurringinbotharms,
with more occurring in the varenicline arm.
For group 2 (no event on either arm; eight trials), “no effect”
was estimated by a risk difference of 0%, but not by relative
effects equal to 1, because the relative summary statistics
exclude trials with no events. For groups 3 and 5 (at least one
event on each arm; six trials), the evidence for and against the
null hypothesis of no treatment effect was similar across the
four statistics in group 3, but the Peto odds ratio seemed to
underestimate treatment effects in group 5.
For every trial in groups 1 and 4 (eight trials), in terms of both
mean effects and confidence intervals, the Peto odds ratio was
farstrongerthantherelativerisk,buttheMantel-Haenszelodds
ratio was nearly identical to the relative risk. In all eight trials,
the Peto odds ratio exceeded 3.4 (or its inverse) despite very
few events, large sample sizes, and differences of only one to
two events by arm. For example, the trial by Bolliger and
colleagues
37 saw one event among 394 participants receiving
varenicline (0.25%) compared with no events among 199
participants receiving placebo (0%) (risk difference 0.25%,
relative risk of 1.52, Mantel-Haenszel odds ratio of 1.52, Peto
odds ratio of 4.50).
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RESEARCHDiscussion
This meta-analysis included all published randomised, placebo
controlled trials of varenicline for tobacco cessation, examined
events occurring during drug exposure or within 30 days of
discontinuation, and analysed findings via four summary
measures. None of these measures identified a significantly
elevated risk of treatment emergent, cardiovascular serious
adverse events with varenicline use, and the 95% confidence
interval of the risk difference excluded an increase larger than
0.63%. In response to the FDA’s call for analysis of
cardiovascular serious adverse events attributed to varenicline
use, this meta-analysis of 22 independent trials and more than
9000individualshadhighpowertodetectasignificanttreatment
effect and found negligible variation in the evidence across the
trials.
Study participants tended to be chronic, heavy smokers,
averaging more than one pack of cigarettes a day for more than
two decades, placing them at elevated risk of serious adverse
events related to cardiovascular disease. Most trials included
individuals with current (two trials) or past (11 trials)
cardiovascular disease. More than a third of studies did not
observe a cardiovascular serious adverse event; among these
trials,fiveofeightincludedparticipantswithpastcardiovascular
disease.
34 40 41 44 46
Comparison with other studies
In their meta-analysis of the safety of varenicline, Singh and
colleagues reported a Peto odds ratio of 1.72 (95% confidence
interval1.09to2.71)andconcludedthat“Theuseofvarenicline
among tobacco users was associated with a 72% increased risk
of serious adverse cardiovascular events.” They questioned the
safety of this medication,
13 and in subsequent press interviews
called for withdrawal of varenicline from the market.
38 The
researchers’ analysis of cardiovascular serious adverse events
at any time during the trial duration was, on average, twice the
duration of study drug exposure and did not account for longer
follow-up in the varenicline group than in the placebo group.
The discrepancy between the conclusions of our meta-analysis
and those of Singh and colleagues’ study is explained not only
by differing periods over which events were collected but also
by the choice of statistics used to summarise the results, which
affected the trials included in the meta-analyses. For direct
comparison in our study, we analysed data from all 22 trials
using the full study follow-up, because the observation period
of interest and the calculated risk difference was 0.47% (95%
confidenceinterval0.04to0.91),farlessinflammatorythanthe
previous meta-analysis’s reported risk based on the Peto odds
ratio, yet still biased in favour of finding an effect due to the
differential inclusion of events related to disease and not just
treatment.Bycontrast,ourcalculatedriskdifferenceoftreatment
emergent, cardiovascular serious events was 0.27% (−0.10 to
0.63).
Choice of summary statistics
When study participants are selected by outcome status (for
example, case or control), an odds ratio must be used to
summariseanassociationwithexposurestatus.However,when
participantsareselectedbyexposurestatus(forexample,active
or placebo treatment), a risk difference or relative risk can be
used. These statistics are more natural choices for randomised
trials because they explicitly estimate and contrast effects of
interest—namely, event rates in the active and placebo arms.
Treatment effects based on relative risks always are as or less
extreme than those based on odds ratios.
30 The (absolute) risk
difference has a further advantage because it can be calculated
for trials in which zero events occur, whereas relative statistics
cannot be calculated for these trials and therefore can bias
summaries against the null hypothesis of “no effect.”
Furthermore, relative statistics are unitless, which hides the fact
that a low response rate remains very low even when scaled up
by a seemingly large effect; by contrast, the risk difference
retains the units of the measurement scale, showing that a
difference between low response rates is itself very small.
Vandermeer and colleagues’ comprehensive reanalysis of
findings from 1613 meta-analyses of safety data indicated that
thePetooddsratiostatisticwasparticularlybiased.
22Wefurther
demonstrate that, regardless of sample size allocation, when all
eventsareinonestudyarm,Mantel-Haenszeloddsratiosmatch
relativeriskswellwhereasPetooddsratiosarefarmoreextreme.
For clinical considerations and in the setting of rare events, the
risk difference most clearly conveys the relevant effect.
22 23 39
Conclusions and clinical implications
Meta-analysis is an important analytical technique for
synthesisingtreatmenteffectsacrosstrialsformaximumpower
and is particularly useful for analysis of serious adverse events,
whichcanoccurwithlowfrequency.Biasinmethods,however,
is a real concern. Our comparison of four summary statistics
identified conditions under which the Peto odds ratio produced
extremeestimatesthatdidnotreflecttheunderlyingeventrates,
andidentifiedcasesinwhichitproducedsmallerestimatesthan
it theoretically should have done. Our results accord with other
reports that the Peto statistic can lead to incorrect
conclusions.
22 29 The consequence of inflated risk estimates,
such as those from Singh and colleagues’ meta-analysis
concerning the effect of varenicline on serious adverse events
related to cardiovascular disease,
13 can be unnecessary public
alarm and real harm, since patients may discontinue their drug
treatment out of fear of adverse effects and clinicians may
recommend cessation treatments of reduced efficacy or
discourage use of the drug treatment altogether.
Smoking is the leading preventable cause of death worldwide.
Half of long term smokers die from their tobacco use, and
smokers die from cardiovascular disease more than from any
other cause.
1-3 Varenicline is a first line treatment for quitting
smoking, and quitting smoking is central to the prevention of
cardiovasculardisease.Ourmeta-analysisoftreatmentemergent,
cardiovascularseriousadverseevents,withattentiontobiasand
critical design issues, indicates that the risk of these events
associated with varenicline use is small, and statistically and
clinically insignificant.
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RESEARCHWhat is already known on this topic
There have been drug safety concerns about the use of varenicline for tobacco cessation and the emergence of cardiovascular serious
adverse events
However, this association has since been called into question, owing to less than optimal methodology used, and the US FDA has called
for further analysis
What this study adds
Our meta-analysis of all published, randomised controlled trials of varenicline use for tobacco cessation included 50% more studies
than a previous meta-analysis by Singh and colleagues; used an unbiased summary estimate and compared findings with three other
estimates; and examined events that occurred during drug treatment, which is more biologically relevant and obviates problems with
differential drop out
All four summary estimates indicated no significant increase in the risk of treatment emergent, cardiovascular serious adverse events
attributed to varenicline use
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RESEARCHTables
Table 1| Characteristics of randomised controlled trials of varenicline included in the meta-analysis
Study
duration
(weeks)
Duration
of
treatment
(weeks) Varenicline dose Cardiac exclusions
Duration
oftobacco
use
(years;
mean)
No of
cigarettes
per day
(mean)
White
participants
(%)
Male
participants
(%) N Study
52 12 1 mg twice daily Cardiovascular procedure in past two
months or cardiovascular instability
(myocardial infarction or unstable angina),
uncontrolled hypertension, significant
neurological sequelae of cerebrovascular
disease, peripheral vascular disease with
39.5 22.5 80.5 78.7 714 Rigotti et al
11
previous amputation, or severe congestive
heart failure
24 12 1 mg twice daily No cardiac exclusions, 57% of sample had
a diagnosis at admission related to
cardiovascular disease
Not
reported
20.0 72 59 79 Steinberg et
al
25
24 12 1 mg twice daily Clinically significant cardiovascular disease
in past six months
24.1 23.1 59.4 76.6 128 Protocol
A3051072
24 12 1 mg twice daily Serious or unstable disease in past six
months (for example, cardiovascular
disease, cerebrovascular disorders),
uncontrolled hypertension or systolic blood
pressure >150 mm Hg or diastolic blood
pressure >95 mm Hg
25.7 23.8 30.6 60.4 593 Bolliger et al
37
24 12 1 mg twice daily Unstable angina, myocardial infarction in
past three months, hypertension with
systolic blood pressure ≥200 mm Hg or
diastolic blood pressure ≥100 mm Hg,
cardiac dysrhythmia other than drug
controlled atrial fibrillation or paroxysmal
supraventricular tachycardia
18.8 Not
applicable
97.4 100 76 Ebbert et al
34
16 12 1 mg twice daily Unstable cardiovascular disease in past six
months
16.9 22.3 75.5 66.4 110 Garza et al
41
52 12 1 mg twice daily Clinically significant cardiovascular disease
in past six months; uncontrolled
hypertension
24.5 21.3 77.9 52.0 696 Gonzales et
al
42
52 12 1 mg twice daily Clinically significant cardiovascular disease
in past six months; uncontrolled
hypertension or systolic blood pressure
>150 mm Hg or diastolic blood pressure
>95mm Hg
25.8 22 85.3 56.6 685 Jorenby et al
43
24 12 1 mg twice daily Unstable serious disease in past six months
(cardiovascular disease not specified)
Not
reported
Not
reported
“Mostly
white”
60 659 Rennard et
al
44
52 12 1 mg twice daily Abnormal electrocardiogram, unstable
cardiovascular disease or history of disease
in past six months; uncontrolled
hypertension or systolic blood pressure
>160 mm Hg or diastolic blood pressure
>95 mm Hg; cerebrovascular events (for
40.5 24.4 83.0 62.3 504 Tashkin et al
45
example, stroke, transient ischaemic attack)
in past six months
40 12 1 mg twice daily Cardiovascular disease within past six
months, uncontrolled hypertension
28.1 20.7 96.9 49.3 1210 Tonstad et al
36
24 12 1 mg twice daily Cardiovascular or cerebrovascular disease
in past six months, uncontrolled
hypertension or systolic blood pressure
>150 mm Hg or diastolic blood pressure
>95 mm Hg) at baseline
20 20.8 0 96.7 333 Wang et al
46
53 52 1 mg twice daily Cardiovascular disease in past six months,
history of hypertension
30.4 23.3 88.6 49.9 377 Williams et
al
47
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Study
duration
(weeks)
Duration
of
treatment
(weeks) Varenicline dose Cardiac exclusions
Duration
oftobacco
use
(years;
mean)
No of
cigarettes
per day
(mean)
White
participants
(%)
Male
participants
(%) N Study
26 12 1 mg twice daily Any serious medical condition
(cardiovascular disease and timing not
specified)
21 Not
applicable
99.3 89.3 432 Fagerstrom et
al
24
10 8 1 mg once daily Major medical conditions, atrioventricular
block identified on electrocardiogram (timing
not specified)
18.8 17.7 Not reported 66 41 Hong et al
26
24 2-8 1 mg twice daily No current or history of medical problems
that would place the participant at
substantial risk of an adverse event
26.3 18.5 91.7 59.1 218 Hughes et al
48
40 12 0.25 mg twice
daily, 0.5 mg
twice daily, 1 mg
twice daily
History of cardiovascular and
cerebrovascular disease
20.9 23.9 0 74.8 619 Nakamura et
al
20
52 12 1 mg twice daily History of cardiovascular disease, abnormal
electrocardiogram, systolic blood pressure
>160 mm Hg or diastolic blood pressure
>95 mm Hg
25.3 22.2 90.7 51.9 320 Niaura et al
49
52 6 0.3 once daily, 1
mg once daily, 1
mg twice daily
History of cardiovascular disease,
uncontrolled hypertension
24.3 20.2 76 49 510 Nides et al
50
52 12 0.5 mg twice
daily, 1 mg twice
daily*
Cardiovascular disease (timing not
specified)
25.2 20.9 80.5 49.5 647 Oncken et al
51
12 12 1 mg twice daily Major cardiovascular disease (timing not
specified)
Not
reported
18.7 61.3 80.6 31 Poling et al
52
24 12 1 mg twice daily Present or history of cardiovascular or
cerebrovascular disease
21.1 23.1 0 88.8 250 Tsai et al
53
Studies ordered according to cardiovascular disease inclusions: current disease, past disease, no history of disease, or timing not specified.
*Two regimens per dose were studied, fixed and progressive.
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RESEARCHTable 2| Risk of treatment emergent, cardiovascular serious adverse events associated with varenicline use in double blind, placebo
controlled randomised trials of tobacco cessation
Treatment effect (95% confidence interval) Allocation
ratio
Events/randomised
participants (no)
Study
between
study
groups
Risk difference (%) Relative risk Odds ratio Peto odds ratio Placebo Varenicline
−0.46 (−1.73 to 0.81) 0.34 (0.01 to 8.29) 0.34 (0.14 to 8.34) 0.14 (0.00 to 6.95) 1:1 1/218 0/214 Fagerstrom et al
24
0 (−0.87 to 0.87) UC UC UC 3:1 0/166 0/493 Rennard et al
44
0 (−3.52 to 3.52) UC UC UC 2:1 0/43 0/85 Protocol A3051072
40
0 (−9.00 to 9.00) UC UC UC 1:1 0/21 0/20 Hong et al
26
0 (−4.99 to 4.99) UC UC UC 1:1 0/38 0/38 Ebbert et al
34
0 (−3.48 to 3.48) UC UC UC 1:1 0/55 0/55 Garza et al
41
0 (−1.78 to 1.78) UC UC UC 1:1 0/111 0/107 Hughes et al
48
0 (−1.17 to 1.17) UC UC UC 1:1 0/168 0/165 Wang et al
46
0 (−12.10 to 12.10) UC UC UC 0.7:1 0/18 0/13 Poling et al
52
−0.06 (−0.07 to 6.87) 0.98 (0.06 to 15.05) 0.97 (0.06 to 16.15) 0.98 (0.06 to 15.87) 1:1 1/39 1/40 Steinberg et al
25
0.00 (−0.81 to 0.81) 0.99 (0.06 to 15.78) 0.99 (0.06 to 15.91) 0.99 (0.06 to 15.88) 1:1 1/341 1/344 Jorenby et al
43
−0.01 (−1.14 to 1.11) 0.98 (0.14 to 6.90) 0.98 (0.14 to 6.98) 0.98 (0.14 to 6.97) 1:1 2/344 2/352 Gonzales et al
42
0.03 (−2.39 to 2.45) 1.01 (0.43 to 2.40) 1.01 (0.42 to 2.46) 1.01 (0.42 to 2.46) 1:1 10/359 10/355 Rigotti et al
11
0.39 (−0.83 to 1.61) 1.25 (0.06 to 25.93) 1.25 (0.06 to 26.27) 3.49 (0.11 to 112.44) 4:1 0/129 2/518 Oncken et al
51
0.26 (−0.99 to 1.51) 1.00 (0.04 to 24.39) 1.00 (0.04 to 24.70) 3.79 (0.04 to 352.09) 3:1 0/127 1/383 Nides et al
50
0.22 (−0.82 to 1.25) 1.00 (0.04 to 24.37) 1.00 (0.04 to 24.62) 3.79 (0.04 to 352.44) 3:1 0/154 1/465 Nakamura et al
20
0.25 (−0.67 to 1.17) 1.52 (0.06 to 37.12) 1.52 (0.06 to 37.51) 4.50 (0.07 to 285.96) 2:1 0/199 1/394 Bolliger et al
37
0.79 (−1.39 to 2.97) 2.95 (0.12 to 71.79) 2.98 (0.12 to 73.76) 7.27 (0.14 to 366.57) 1:1 0/124 1/126 Tsai et al
53
1.25 (−0.84 to 3.34) 5.00 (0.24 to 103.33) 5.06 (0.24 to 106.30) 7.44 (0.46 to 119.40) 1:1 0/160 2/160 Niaura et al
49
0.33 (−0.23 to 0.89) 5.03 (0.24 to 104.62) 5.05 (0.24 to 105.41) 7.45 (0.47 to 119.26) 1:1 0/607 2/603 Tonstad et al
36
1.60 (−0.85 to 4.04) 3.01 (0.37 to 24.75) 3.06 (0.37 to 25.71) 2.40 (0.49 to 11.67) 2:1 1/126 6/251 Williams et al
47
0.81 (−1.08 to 2.71) 2.03 (0.38 to 10.99) 2.05 (0.37 to 11.29) 1.99 (0.40 to 9.95) 1:1 2/254 4/250 Tashkin et al
45
0.27 (−0.10 to 0.63) 1.40 (0.82 to 2.39) 1.41 (0.82 to 2.42) 1.58 (0.90 to 2.76) — 18/3801 34/5431 All trials combined
Studies grouped by presence (v absence) of events and equal (v unequal) numbers of events; groups ordered by increasing evidence of a varenicline effect.
UC=unable to calculate using Peto odds ratio, Mantel-Haenszel odds ratio, and relative risk because no events in either group.
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RESEARCHFigures
Fig 1 Literature search results and study selection
Fig 2 Difference in risk of treatment emergent, cardiovascular serious adverse events associated with varenicline use in
22 double blinded, placebo controlled, randomised trials. Studies grouped by presence (v absence) of events and equal (v
unequal) numbers of events with groups ordered by increasing evidence of a varenicline effect
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RESEARCHFig 3 Cumulative estimated difference in risk of cardiovascular serious adverse events attributable to varenicline use.
Studies ordered by publication year
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